Medtronic (MDT) Earnings Date & Reports

Key Takeaways

• Revenue beat: Q4 fiscal 2026 revenue reached $9.81 billion, up 9.9% reported and 6.6% organically, exceeding consensus estimates by approximately $194 million.
• Non-GAAP EPS of $1.55 came in ahead of company guidance, though it declined 4.3% year-over-year due to margin headwinds including tariffs and one-time payments.
• Cardiac Ablation Solutions (CAS) emerged as the standout growth engine, surging 78% worldwide and gaining 8 points of U.S. market share, with pulsed field ablation (PFA) growing 145% globally.
• Full-year FY26 revenue of $36.4 billion marked the company's strongest annual top-line performance in a decade, with 8.4% reported growth and 5.8% organic growth.
• FY27 guidance calls for 6.75%–7.25% organic revenue growth and adjusted EPS of $5.90–$6.00, factoring in an estimated $250 million tariff impact.
• Dividend raised to $0.72 per share quarterly, marking the 49th consecutive year of dividend increases.

Earnings Context and Why It Matters

Medtronic's fourth-quarter fiscal 2026 results, released on June 3, 2026, carried outsized importance for investors evaluating whether the world's largest standalone medical device company could sustain momentum across its diversified portfolio. Coming off several quarters of accelerating growth, the report served as a litmus test for management's multi-year transformation strategy centered on high-growth platforms such as cardiac ablation, surgical robotics, and renal denervation. The quarter also captured the completed MiniMed IPO (Initial Public Offering) — a milestone in Medtronic's effort to sharpen its focus on higher-margin, technology-intensive businesses. With procedure volumes normalizing across global healthcare systems and tariff policy introducing fresh cost uncertainty, these results offered a timely read on Medtronic's resilience and execution capability heading into fiscal 2027.

Reported Results

Medtronic reported Q4 fiscal 2026 worldwide revenue of $9.807 billion, a 9.9% increase on a reported basis and 6.6% on an organic basis, exceeding the Zacks Consensus Estimate of $9.61 billion by roughly 1.5%. The results landed approximately 90 basis points (bps) ahead of the company's own implied guidance. For the full fiscal year 2026, revenue totaled $36.36 billion, up 8.4% reported and 5.8% organically — the strongest annual top-line growth in 10 years.

On the bottom line, Q4 GAAP (Generally Accepted Accounting Principles) diluted EPS was $0.96, up 17.1% year-over-year. Non-GAAP diluted EPS came in at $1.55, declining 4.3% from the prior-year quarter but beating the Zacks Consensus Estimate of $1.54. For fiscal 2026, non-GAAP diluted EPS was $5.53, a 0.7% increase from the prior year.

Segment-level highlights included the Cardiovascular Portfolio, which generated $3.80 billion — up 13.8% reported and 10.1% organic — powered by a 78% surge in Cardiac Ablation Solutions. The Neuroscience Portfolio contributed $2.75 billion, up 5.0% reported and 3.0% organic, while the Medical Surgical Portfolio delivered $2.39 billion, up 8.0% reported and 5.1% organic. The Diabetes business posted $837 million in revenue, up 15.0% reported and 8.1% organic.

Adjusted gross margin expanded 30 bps year-over-year to 65.4%, supported by pricing discipline and cost-of-goods efficiencies. However, adjusted operating margin contracted 230 bps to 25.5%, reflecting 160 bps from the MiniMed Blackstone milestone payment and 80 bps from tariffs. Free cash flow reached $5.4 billion for the year, with $9.2 billion in cash and investments at year-end.

AI Screener

For investors seeking to identify emerging opportunities across the medtech landscape or broader equity markets, Tickeron's AI Screener offers a powerful AI-driven stock and ETF (Exchange-Traded Fund) discovery tool. The platform allows users to scan thousands of securities using customizable filters such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and proprietary AI-generated signals. Whether tracking breakout candidates, trending sectors, or mean-reversion setups, the AI Screener is designed to surface relevant trade ideas with greater speed and precision than conventional manual screening methods. Traders and investors can explore the tool to complement their own research workflows and stay ahead of shifting market conditions.

Market Reaction and Investor Sentiment

MDT shares rose approximately 2% in pre-market trading on June 3, 2026, following the earnings release, reflecting an initially favorable response to the revenue and EPS beats. The market appeared to reward the company's broad-based top-line strength — particularly the exceptional performance in Cardiac Ablation Solutions — while largely looking past the year-over-year decline in non-GAAP EPS and the 230-bps contraction in adjusted operating margin. Sentiment was further supported by the dividend increase and the company's confident FY27 guidance, which signaled management's conviction in sustained organic growth despite tariff headwinds. However, flat performance in Structural Heart and ongoing margin pressures from tariffs and one-time payments tempered outright bullishness. Analysts on the earnings call probed the sustainability of CAS growth rates and the pace of margin recovery, indicating that these two variables remain central to the investment narrative heading into the new fiscal year.

Forward Outlook and Key Factors to Monitor

Medtronic's fiscal 2027 guidance sets an ambitious tone, targeting organic revenue growth of 6.75% to 7.25% and non-GAAP EPS of $5.90 to $6.00 — implying EPS growth of 6.7% to 8.5%. This outlook incorporates several moving parts that investors should track closely.

First, the guidance assumes an additional selling week in FY27, contributing roughly 125 bps to full-year organic growth. Stripping that out, underlying growth expectations remain solid. Second, management has explicitly baked in a $250 million tariff impact to cost of goods sold, with no assumption of government reimbursement. This headwind, concentrated in Q1 at $75 million, will pressure gross margins by an estimated 20 bps year-over-year. Excluding tariffs, gross margin is expected to be roughly flat, and operating margin is projected to expand about 60 bps — helped by the absence of Blackstone milestone payments.

Key catalysts to monitor include the continued ramp of the Affera pulsed field ablation platform, the U.S. rollout of Hugo robotic-assisted surgery (pending FDA clearance for general surgery and gynecologic indications), and the commercial scaling of Symplicity Spyral for renal denervation. The stabilization of the TAVR (Transcatheter Aortic Valve Replacement) business within Structural Heart will also be closely watched after a period of U.S. softness. Additionally, the pace and integration of tuck-in M&A (Mergers and Acquisitions) — including the planned acquisitions of Scientia Vascular and SPR Therapeutics — could influence both growth and margin trajectories in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations